{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:40:54Z","timestamp":1790106054206,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260720"],"award-info":[{"award-number":["82260720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224ACB206033"],"award-info":[{"award-number":["20224ACB206033"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>AXL, a receptor tyrosine kinase, has recently emerged as a potential therapeutic target against various types of cancer. Gilteritinib, a FDA-approved small-molecule inhibitor, is used for the treatment of patients with FLT3-mutated acute myeloid leukemia. However, the antitumor activity of gilteritinib in solid tumors remains poorly elucidated. In this study, we explored the antitumor activity of gilteritinib in AXL-expressing esophageal cancer (EC), ovarian cancer (OC), and gastric cancer (GC), along with the underlying molecular mechanisms. Our data demonstrated that gilteritinib significantly inhibited cell proliferation and spheroid formation by triggering apoptosis and cell cycle arrest in AXL-positive EC, OC, and GC cells. Moreover, we found that gilteritinib treatment repressed EC, OC, and GC cell migration and invasion. Mechanistically, RNA-seq analysis revealed that gilteritinib significantly downregulated multiple cancer-related pathways, including those related to apoptosis, the cell cycle, the mTOR pathway, the AMPK pathway, the p53 pathway, the FOXO pathway, the Hippo pathway, and the Wnt pathway. Gilteritinib inhibited a unique set of E2F- and MYC target-associated genes in EC, OC, and GC cells. Intriguingly, interrogation of the EC, OC, and GC cohort demonstrated that these genes were overexpressed and associated with poor prognosis. Gilteritinib also displayed strong antitumor effects on AXL-positive PDX-derived explants (PDXEs) and PDX-derived organoids (PDXOs) ex vivo and PDXs in vivo. Collectively, these findings reveal that gilteritinib represents a potent therapeutic agent for the treatment of AXL-positive solid tumors.<\/jats:p>","DOI":"10.1038\/s41420-025-02417-9","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:16:37Z","timestamp":1743272197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors"],"prefix":"10.1038","volume":"11","author":[{"given":"Zuxiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youban","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-2682","authenticated-orcid":false,"given":"Shuyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-4533","authenticated-orcid":false,"given":"Liefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"2417_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2417_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2417_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn3774","volume":"8","author":"L Qin","year":"2022","unstructured":"Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, et al. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv. 2022;8:eabn3774.","journal-title":"Sci Adv"},{"key":"2417_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/cancers14030554","volume":"14","author":"H Teixeira Farinha","year":"2022","unstructured":"Teixeira Farinha H, Digklia A, Schizas D, Demartines N, Schafer M, Mantziari S. Immunotherapy for esophageal cancer: state-of-the art in 2021. Cancers. 2022;14:554.","journal-title":"Cancers"},{"key":"2417_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35:151\u20136.","journal-title":"Semin Oncol Nurs"},{"key":"2417_CR6","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.7150\/thno.53828","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, et al. Biocompatible AIEgen\/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Theranostics. 2021;11:3710\u201324.","journal-title":"Theranostics"},{"key":"2417_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lfs.2018.02.033","volume":"198","author":"Y Shen","year":"2018","unstructured":"Shen Y, Chen X, He J, Liao D, Zu X. Axl inhibitors as novel cancer therapeutic agents. Life Sci. 2018;198:99\u2013111.","journal-title":"Life Sci"},{"key":"2417_CR8","first-page":"2113","volume":"6","author":"JW Janssen","year":"1991","unstructured":"Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene. 1991;6:2113\u201320.","journal-title":"Oncogene"},{"key":"2417_CR9","first-page":"5016","volume":"11","author":"JP O\u2019Bryan","year":"1991","unstructured":"O\u2019Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11:5016\u201331.","journal-title":"Mol Cell Biol"},{"key":"2417_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57\u201370.","journal-title":"Cell"},{"key":"2417_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","volume":"100","author":"RM Linger","year":"2008","unstructured":"Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35\u201383.","journal-title":"Adv Cancer Res"},{"key":"2417_CR12","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2174\/0929867323666160405112954","volume":"23","author":"C Corno","year":"2016","unstructured":"Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P. Role of the receptor tyrosine kinase Axl and its targeting in cancer cells. Curr Med Chem. 2016;23:1496\u2013512.","journal-title":"Curr Med Chem"},{"key":"2417_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ijc.28246","volume":"134","author":"JD Paccez","year":"2014","unstructured":"Paccez JD, Vogelsang M, Parker MI, Zerbini LF. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer. 2014;134:1024\u201333.","journal-title":"Int J Cancer"},{"key":"2417_CR14","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.18632\/oncotarget.2542","volume":"5","author":"X Wu","year":"2014","unstructured":"Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014;5:9546\u201363.","journal-title":"Oncotarget"},{"key":"2417_CR15","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-14-2648","volume":"21","author":"TM Brand","year":"2015","unstructured":"Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:2601\u201312.","journal-title":"Clin Cancer Res"},{"key":"2417_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.27492","volume":"61","author":"P Reichl","year":"2015","unstructured":"Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, et al. Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. Hepatology. 2015;61:930\u201341.","journal-title":"Hepatology"},{"key":"2417_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, et al. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investig New Drugs. 2017;35:556\u201365.","journal-title":"Investig New Drugs"},{"key":"2417_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Gilteritinib: first global approval. Drugs. 2019;79:331\u20139.","journal-title":"Drugs"},{"key":"2417_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","volume":"4","author":"M Levis","year":"2020","unstructured":"Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4:1178\u201391.","journal-title":"Blood Adv"},{"key":"2417_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","volume":"129","author":"LY Lee","year":"2017","unstructured":"Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129:257\u201360.","journal-title":"Blood"},{"key":"2417_CR21","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"IK Park","year":"2015","unstructured":"Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29:2382\u20139.","journal-title":"Leukemia"},{"key":"2417_CR22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2217\/fon-2017-0582","volume":"14","author":"CM Gorcea","year":"2018","unstructured":"Gorcea CM, Burthem J, Tholouli E. ASP2215 in the treatment of relapsed\/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Future Oncol. 2018;14:1995\u20132004.","journal-title":"Future Oncol"},{"key":"2417_CR23","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.22.02721","volume":"41","author":"KW Pratz","year":"2023","unstructured":"Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase ib study in patients with newly diagnosed AML. J Clin Oncol. 2023;41:4236\u201346.","journal-title":"J Clin Oncol"},{"key":"2417_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","volume":"116","author":"Y Arai","year":"2022","unstructured":"Arai Y, Chi S, Minami Y, Yanada M. FLT3-targeted treatment for acute myeloid leukemia. Int J Hematol. 2022;116:351\u201363.","journal-title":"Int J Hematol"},{"key":"2417_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106\u201310.","journal-title":"Nature"},{"key":"2417_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111\u20135.","journal-title":"Nature"},{"key":"2417_CR27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124\u201334.","journal-title":"Nat Med"},{"key":"2417_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fendo.2019.00682","volume":"10","author":"G Bresciani","year":"2019","unstructured":"Bresciani G, Hofland LJ, Dogan F, Giamas G, Gagliano T, Zatelli MC. Evaluation of spheroid 3D culture methods to study a pancreatic neuroendocrine neoplasm cell line. Front Endocrinol. 2019;10:682.","journal-title":"Front Endocrinol"},{"key":"2417_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50968-6","volume":"9","author":"K Tsunekuni","year":"2019","unstructured":"Tsunekuni K, Konno M, Haraguchi N, Koseki J, Asai A, Matsuoka K, et al. CD44\/CD133-positive colorectal cancer stem cells are sensitive to trifluridine exposure. Sci Rep. 2019;9:14861.","journal-title":"Sci Rep"},{"key":"2417_CR30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/cancers12051304","volume":"12","author":"R Amaral","year":"2020","unstructured":"Amaral R, Zimmermann M, Ma AH, Zhang H, Swiech K, Pan CX. A simple three-dimensional in vitro culture mimicking the in vivo-like cell behavior of bladder patient-derived xenograft models. Cancers. 2020;12:1304.","journal-title":"Cancers"},{"key":"2417_CR31","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119:1420\u20138.","journal-title":"J Clin Investig"},{"key":"2417_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2417_CR33","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/0008-5472.CAN-16-1121","volume":"77","author":"E Karekla","year":"2017","unstructured":"Karekla E, Liao WJ, Sharp B, Pugh J, Reid H, Quesne JL, et al. Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Res. 2017;77:2029\u201339.","journal-title":"Cancer Res"},{"key":"2417_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2019.11.020","volume":"156","author":"A Collins","year":"2020","unstructured":"Collins A, Miles GJ, Wood J, MacFarlane M, Pritchard C, Moss E. Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer. Gynecol Oncol. 2020;156:251\u20139.","journal-title":"Gynecol Oncol"},{"key":"2417_CR35","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013.","journal-title":"Cancer Discov"},{"key":"2417_CR36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21:1318\u201325.","journal-title":"Nat Med"},{"key":"2417_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462\u201377.","journal-title":"Cancer Discov"},{"key":"2417_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell. 2020;26:17\u201326 e16.","journal-title":"Cell Stem Cell"},{"key":"2417_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/cancers15010139","volume":"15","author":"KF Idrisova","year":"2022","unstructured":"Idrisova KF, Simon HU, Gomzikova MO. Role of patient-derived models of cancer in translational oncology. Cancers. 2022;15:139.","journal-title":"Cancers"},{"key":"2417_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17512433.2023.2174523","volume":"16","author":"A Solana-Altabella","year":"2023","unstructured":"Solana-Altabella A, Megias-Vericat JE, Ballesta-Lopez O, Martinez-Cuadron D, Montesinos P. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert Rev Clin Pharmacol. 2023;16:133\u201348.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2417_CR41","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","volume":"110","author":"AJ Mead","year":"2007","unstructured":"Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110:1262\u201370.","journal-title":"Blood"},{"key":"2417_CR42","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776\u201384.","journal-title":"Blood"},{"key":"2417_CR43","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, Ronnstrand L. FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev. 2019;99:1433\u201366.","journal-title":"Physiol Rev"},{"key":"2417_CR44","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1038\/onc.2009.212","volume":"28","author":"Y Li","year":"2009","unstructured":"Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28:3442\u201355.","journal-title":"Oncogene"},{"key":"2417_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.0909333107","volume":"107","author":"C Gjerdrum","year":"2010","unstructured":"Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107:1124\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2417_CR46","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1038\/onc.2010.268","volume":"29","author":"X Ye","year":"2010","unstructured":"Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010;29:5254\u201364.","journal-title":"Oncogene"},{"key":"2417_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrc3310","volume":"12","author":"O Rath","year":"2012","unstructured":"Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer. 2012;12:527\u201339.","journal-title":"Nat Rev Cancer"},{"key":"2417_CR48","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1158\/1535-7163.MCT-14-0083-T","volume":"13","author":"PP Kung","year":"2014","unstructured":"Kung PP, Martinez R, Zhu Z, Zager M, Blasina A, Rymer I, et al. Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer. Mol Cancer Ther. 2014;13:2104\u201315.","journal-title":"Mol Cancer Ther"},{"key":"2417_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.711642","volume":"11","author":"Q Luo","year":"2021","unstructured":"Luo Q, He W, Mao T, Leng X, Wu H, Li W, et al. MMS22L expression as a predictive biomarker for the efficacy of neoadjuvant chemoradiotherapy in oesophageal squamous cell carcinoma. Front Oncol. 2021;11:711642.","journal-title":"Front Oncol"},{"key":"2417_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12957-022-02667-2","volume":"20","author":"Y Fang","year":"2022","unstructured":"Fang Y, Liu J, Zhang Q, She C, Zheng R, Zhang R, et al. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates. World J Surg Oncol. 2022;20:211.","journal-title":"World J Surg Oncol"},{"key":"2417_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1025970","volume":"13","author":"Z Guo","year":"2022","unstructured":"Guo Z, Liu F, Gong Q. Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma. Front Genet. 2022;13:1025970.","journal-title":"Front Genet"},{"key":"2417_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.947054","volume":"12","author":"A Hu","year":"2022","unstructured":"Hu A, Wang Y, Tian J, Chen Z, Chen R, Han X, et al. Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types. Front Oncol. 2022;12:947054.","journal-title":"Front Oncol"},{"key":"2417_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2023.110595","volume":"115","author":"X Cai","year":"2023","unstructured":"Cai X, Zhu S. Prognosis-related VDAC1 regulates the proliferation and apoptosis of osteosarcoma cells via the MAPK signaling pathway. Genomics. 2023;115:110595.","journal-title":"Genomics"},{"key":"2417_CR54","doi-asserted-by":"crossref","unstructured":"Tan Y, Ding L, Li G. MCM4 acts as a biomarker for LUAD prognosis. J Cell Mol Med. 2023;27:3354\u201362.","DOI":"10.1111\/jcmm.17819"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02417-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:13:18Z","timestamp":1743451998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02417-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2417"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02417-9","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}